Literature DB >> 35102343

Group 3 innate lymphoid cells produce the growth factor HB-EGF to protect the intestine from TNF-mediated inflammation.

Lei Zhou1,2,3, Wenqing Zhou4,5,6, Ann M Joseph4,5,6, Coco Chu6, Gregory G Putzel6, Beibei Fang7, Fei Teng4,5,6, Mengze Lyu4,5,6, Hiroshi Yano6, Katrin I Andreasson8, Eisuke Mekada9, Gerard Eberl10, Gregory F Sonnenberg11,12,13.   

Abstract

Tumor necrosis factor (TNF) drives chronic inflammation and cell death in the intestine, and blocking TNF is a therapeutic approach in inflammatory bowel disease (IBD). Despite this knowledge, the pathways that protect the intestine from TNF are incompletely understood. Here we demonstrate that group 3 innate lymphoid cells (ILC3s) protect the intestinal epithelium from TNF-induced cell death. This occurs independent of interleukin-22 (IL-22), and we identify that ILC3s are a dominant source of heparin-binding epidermal growth factor-like growth factor (HB-EGF). ILC3s produce HB-EGF in response to prostaglandin E2 (PGE2) and engagement of the EP2 receptor. Mice lacking ILC3-derived HB-EGF exhibit increased susceptibility to TNF-mediated epithelial cell death and experimental intestinal inflammation. Finally, human ILC3s produce HB-EGF and are reduced from the inflamed intestine. These results define an essential role for ILC3-derived HB-EGF in protecting the intestine from TNF and indicate that disruption of this pathway contributes to IBD.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35102343      PMCID: PMC8842850          DOI: 10.1038/s41590-021-01110-0

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   31.250


  52 in total

Review 1.  TNF biology, pathogenic mechanisms and emerging therapeutic strategies.

Authors:  George D Kalliolias; Lionel B Ivashkiv
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

Review 2.  The biology of innate lymphoid cells.

Authors:  David Artis; Hergen Spits
Journal:  Nature       Date:  2015-01-15       Impact factor: 49.962

Review 3.  Current and emerging therapeutic targets for IBD.

Authors:  Markus F Neurath
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-02-01       Impact factor: 46.802

Review 4.  Innate Lymphoid Cells: 10 Years On.

Authors:  Eric Vivier; David Artis; Marco Colonna; Andreas Diefenbach; James P Di Santo; Gérard Eberl; Shigeo Koyasu; Richard M Locksley; Andrew N J McKenzie; Reina E Mebius; Fiona Powrie; Hergen Spits
Journal:  Cell       Date:  2018-08-23       Impact factor: 41.582

Review 5.  Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease.

Authors:  Matthias Friedrich; Mathilde Pohin; Fiona Powrie
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 6.  Tumor necrosis factor: a pleiotropic cytokine and therapeutic target.

Authors:  K J Tracey; A Cerami
Journal:  Annu Rev Med       Date:  1994       Impact factor: 13.739

Review 7.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

Review 8.  Pathway paradigms revealed from the genetics of inflammatory bowel disease.

Authors:  Daniel B Graham; Ramnik J Xavier
Journal:  Nature       Date:  2020-02-26       Impact factor: 49.962

Review 9.  Cell death in the gut epithelium and implications for chronic inflammation.

Authors:  Jay V Patankar; Christoph Becker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-10       Impact factor: 46.802

Review 10.  Innate lymphoid cells--a proposal for uniform nomenclature.

Authors:  Hergen Spits; David Artis; Marco Colonna; Andreas Diefenbach; James P Di Santo; Gerard Eberl; Shigeo Koyasu; Richard M Locksley; Andrew N J McKenzie; Reina E Mebius; Fiona Powrie; Eric Vivier
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106

View more
  3 in total

Review 1.  Plasticity of Innate Lymphoid Cells in Cancer.

Authors:  Bernd Heinrich; Firouzeh Korangy
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

2.  Intestinal barrier protection.

Authors:  Kirsty Minton
Journal:  Nat Rev Immunol       Date:  2022-03       Impact factor: 53.106

3.  Identification of HBEGF+ fibroblasts in the remission of rheumatoid arthritis by integrating single-cell RNA sequencing datasets and bulk RNA sequencing datasets.

Authors:  Nachun Chen; Baoying Fan; Zhiyong He; Xinping Yu; Jinjun Wang
Journal:  Arthritis Res Ther       Date:  2022-09-06       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.